In Simple Terms
Frozen Arctic soil preserves traces of tiny organisms that lived long ago. Scientists are studying those traces to see whether they can lead to new medicines, but turning a clue into a treatment is difficult, expensive work. They must also ensure that Indigenous communities’ knowledge and resources are respected and that any benefits are shared fairly.
What Can Frozen Soil Preserve?
Samples of permafrost and Arctic sediment contain genetic material that has accumulated over long periods. Some of it has been damaged by time, so researchers rarely get a complete, pristine picture. Even fragments, though, may reveal information about organisms that no longer live in the area or that science has barely studied.
Srijak Bhatnagar, who leads a research group in bioinformatics and environmental microbiology at Athabasca University, describes these samples as a historical record of microscopic life. Over several years, his team has collected environmental genetic material from waters in the Canadian Arctic. The samples could reveal microbes adapted to extreme cold or ancient strains that routine surveys might miss.
Finding genetic traces does not mean finding a living organism that can be grown, or a ready-made medicine. Researchers must analyze the material, identify genes that might be involved in making a compound, and then test that idea using other methods. The process starts with reading a damaged molecular record and ends only when scientists understand what the genes do, produce the compound, and verify its properties.
Searching for Genes That Won’t Grow in the Lab
For a long time, the difficulty of growing microbes was a major obstacle to discovering the compounds they make. Researchers estimate that about 99 percent of environmental microbes could not be cultivated using traditional laboratory methods. If a microbe will not grow in a lab dish, scientists cannot easily observe what it produces or study its chemistry directly. As a result, much of microbial diversity remained beyond the reach of standard tools.
Analyzing genetic material collected from the environment, along with sequencing DNA from individual cells, can help overcome some of that barrier. Instead of waiting for a microbe to grow, researchers can collect its genetic material from a sample, analyze it on a computer, and build a picture of its genome. They can then search for sets of genes that may work together to make a natural compound. These sets are known as biosynthetic gene clusters.
Justin Nodwell’s lab at the University of Toronto is working to transfer these clusters into bacteria of the genus Streptomyces and use synthetic biology tools to prompt them to produce compounds. The idea is that a host microbe that is easy to handle in the lab may be able to read genetic instructions taken from another organism, even if the original cannot be grown. This approach could help researchers test genes that remain inactive under ordinary growing conditions and perhaps produce natural compounds that were previously out of reach.
From Genetic Code to Compound: A Long, Costly Road
Identifying an intriguing gene cluster does not mean researchers can immediately make a medicine. Some clusters are enormous, reaching roughly 100,000 DNA base pairs. Building or assembling that much DNA takes substantial effort and resources. Making many smaller copies along the way can require a large number of lab reactions, turning each project into a technical and financial challenge.
Another challenge is figuring out where a cluster begins and ends. Some genes may clearly appear to be involved in making a molecule, while the role of nearby genes is uncertain: do they help produce the compound, or do they serve another purpose? If scientists do not know the chemical pathway that makes the molecule, deciding which genes to transfer becomes difficult. Researchers must combine computer analysis with experiments and may need to test several possibilities before they find the right combination.
Moving genetic instructions from a cold-adapted microbe into a lab host accustomed to warmer conditions is no sure thing, either. Genes that work in their original environment may behave differently in another organism. Adapting a cluster to its new host takes modifications and testing, so finding the genes does not automatically mean the desired compound will be produced.
Could Arctic Traces Lead to New Medicines?
Searching environments that have received little study raises hopes of finding compounds unlike those that have been tested again and again. Specialized microbial metabolism has already provided a number of medicines, including cancer drugs such as doxorubicin and rapamycin. Those examples prompt a question: what might scientists find in a harsh, isolated environment like the Arctic, where organisms have faced unusual conditions?
Still, researchers do not expect every new gene to lead to a treatment or every natural compound to become a medicine. Studies of unfamiliar environments often turn up compounds that are already known—a problem sometimes called rediscovery. Scientists must therefore check that a substance found in a sample is not simply a version of one identified before. Even if the compound is new, researchers still need to understand it and determine whether it can be produced at a useful scale before making claims about its medical value.
The value of Arctic exploration, then, cannot be measured only by how quickly it yields new medicines. It may also deepen our understanding of microbial diversity and the pathways organisms use to make compounds. The result could be a promising molecule, new genetic insight, or a lesson about the limits of current analysis and manufacturing techniques. Researchers caution against inflated expectations: moving from a signal in the data to a treatment that can be distributed takes many steps, none of which can be skipped.
Who Owns Knowledge Drawn from the Arctic?
The questions do not stop at lab benches and budgets. When genetic data are placed in public databases, researchers and companies around the world can access and analyze them. Bhatnagar warns that a commercial organization outside Canada could use the data to develop a valuable product, while the communities connected to the resources or knowledge receive no fair share of the benefits.
The issue is especially important for Indigenous peoples who live in the Canadian Arctic. Traditional knowledge about plants, remedies, and the environment may be part of a living cultural heritage, not simply information that can be separated from the people who hold it. The source notes that Canada is not a party to the Nagoya Protocol on access to genetic resources and benefit-sharing, raising questions about how the biological and cultural rights of these communities can be protected.
Past examples from other regions offer reason for caution: traditional knowledge has sometimes been collected, and substances derived from it later isolated and claimed for commercial protection, without adequate regard for the communities that had preserved and used that knowledge for generations. Collecting samples and publishing genetic sequences, then, should not be treated as purely technical matters. Questions about where knowledge comes from, who consents to its use, and who benefits from what it produces must be addressed from the start—not only after a project succeeds.
The Bottom Line
Frozen Arctic soil offers a window into past microbial life, and its genes may reveal chemical pathways that could one day help researchers find antibiotics or other medicines. Turning that possibility into a treatment means overcoming the challenges of reading ancient genetic material, getting it to work in a suitable host, assembling large and costly gene clusters, and confirming that the resulting compound is both new and usable. At the same time, Indigenous rights must be respected and benefits shared fairly. The success of this exploration depends not only on what scientists can uncover, but also on whether they do so responsibly.